Alzinova AB (publ) (ALZ.ST)
SEK 3.5
(0.0%)
SEK 3.5
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 19.87 Million SEK | -149.67% |
| 2022 | 33.26 Million SEK | -3.97% |
| 2021 | 34.64 Million SEK | 16.27% |
| 2020 | 29.79 Million SEK | 118.8% |
| 2019 | 13.61 Million SEK | -27.21% |
| 2018 | 18.7 Million SEK | 71.07% |
| 2017 | 10.93 Million SEK | 7.81% |
| 2016 | 10.14 Million SEK | 915.94% |
| 2015 | 998.38 Thousand SEK | 326.23% |
| 2014 | 234.23 Thousand SEK | 32.1% |
| 2013 | 177.31 Thousand SEK | -8.16% |
| 2012 | 193.06 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -4.96 Million SEK | -3.14% |
| 2024 Q2 | 2.88 Million SEK | 158.12% |
| 2023 Q2 | 12.03 Million SEK | 28.81% |
| 2023 Q4 | -4.81 Million SEK | -172.92% |
| 2023 Q1 | 9.34 Million SEK | 37.32% |
| 2023 FY | -16.52 Million SEK | -149.67% |
| 2023 Q3 | 6.6 Million SEK | -45.17% |
| 2022 Q4 | 6.8 Million SEK | 5.01% |
| 2022 Q3 | 6.48 Million SEK | 5.61% |
| 2022 FY | 33.26 Million SEK | -3.97% |
| 2022 Q2 | 6.13 Million SEK | -55.69% |
| 2022 Q1 | 13.84 Million SEK | 154.24% |
| 2021 Q3 | 4.73 Million SEK | -55.11% |
| 2021 FY | 34.64 Million SEK | 16.27% |
| 2021 Q1 | 13.91 Million SEK | 91.73% |
| 2021 Q2 | 10.54 Million SEK | -24.25% |
| 2021 Q4 | 5.44 Million SEK | 15.06% |
| 2020 Q2 | 4.28 Million SEK | -64.91% |
| 2020 FY | 29.79 Million SEK | 118.8% |
| 2020 Q4 | 7.26 Million SEK | 19.98% |
| 2020 Q3 | 6.05 Million SEK | 41.32% |
| 2020 Q1 | 12.2 Million SEK | 183.39% |
| 2019 Q1 | 4.08 Million SEK | 722.27% |
| 2019 Q4 | 4.3 Million SEK | 74.03% |
| 2019 Q2 | 2.74 Million SEK | -32.73% |
| 2019 Q3 | 2.47 Million SEK | -10.02% |
| 2019 FY | 13.61 Million SEK | -27.21% |
| 2018 Q2 | 6.1 Million SEK | -10.17% |
| 2018 Q1 | 6.79 Million SEK | 79.8% |
| 2018 FY | 18.7 Million SEK | 71.07% |
| 2018 Q4 | 497.1 Thousand SEK | -90.65% |
| 2018 Q3 | 5.31 Million SEK | -12.81% |
| 2017 Q3 | 2.87 Million SEK | 6.11% |
| 2017 Q2 | 2.7 Million SEK | 70.92% |
| 2017 Q1 | 1.58 Million SEK | 30.02% |
| 2017 FY | 10.93 Million SEK | 7.81% |
| 2017 Q4 | 3.77 Million SEK | 31.41% |
| 2016 Q2 | 1.61 Million SEK | 12.05% |
| 2016 Q4 | 1.21 Million SEK | 25.07% |
| 2016 Q1 | 1.44 Million SEK | 115.75% |
| 2016 FY | 10.14 Million SEK | 915.94% |
| 2016 Q3 | 974.57 Thousand SEK | -39.72% |
| 2015 Q4 | 668.75 Thousand SEK | 484.52% |
| 2015 Q1 | 98.81 Thousand SEK | -30.28% |
| 2015 FY | 998.38 Thousand SEK | 326.23% |
| 2015 Q3 | 114.41 Thousand SEK | -1.71% |
| 2015 Q2 | 116.4 Thousand SEK | 17.8% |
| 2014 FY | 234.23 Thousand SEK | 32.1% |
| 2014 Q4 | 141.72 Thousand SEK | 0.0% |
| 2013 FY | 177.31 Thousand SEK | -8.16% |
| 2012 FY | 193.06 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 112.368% |
| Ziccum AB (publ) | -23.28 Million SEK | 185.347% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 94.261% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 52.44% |
| Mendus AB (publ) | 28.48 Million SEK | 30.235% |
| Genovis AB (publ.) | 54 Million SEK | 63.197% |
| Intervacc AB (publ) | -13.79 Million SEK | 244.077% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -815.431% |
| Active Biotech AB (publ) | -1.67 Million SEK | 1286.507% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | -99.478% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 25.901% |
| Aptahem AB (publ) | 2.63 Million SEK | -655.479% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 680.941% |
| Kancera AB (publ) | -1.96 Million SEK | 1111.399% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -25710.39% |
| Fluicell AB (publ) | 1.73 Million SEK | -1043.498% |
| Saniona AB (publ) | 11.78 Million SEK | -68.695% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 488.392% |
| Biovica International AB (publ) | 6.87 Million SEK | -188.992% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 185.358% |
| AcouSort AB (publ) | 8.38 Million SEK | -136.905% |
| Xintela AB (publ) | 78 Thousand SEK | -25379.487% |
| Abliva AB (publ) | -35.66 Million SEK | 155.727% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 113.529% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -608.016% |
| OncoZenge AB (publ) | 3000.00 SEK | -662366.667% |
| Amniotics AB (publ) | -1.93 Million SEK | 1129.741% |
| 2cureX AB (publ) | -37.48 Million SEK | 153.016% |
| CombiGene AB (publ) | -21.29 Million SEK | 193.346% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 4798.345% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 98.241% |
| Camurus AB (publ) | 1.58 Billion SEK | 98.743% |
| Corline Biomedical AB | 28.38 Million SEK | 29.972% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 116.193% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 157.748% |
| I-Tech AB | 27.56 Million SEK | 27.904% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 71.989% |
| Cyxone AB (publ) | 2.61 Million SEK | -661.164% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | -484.014% |
| Biosergen AB | -456 Thousand SEK | 4458.333% |
| Cantargia AB (publ) | -3.45 Million SEK | 675.891% |
| NextCell Pharma AB | -43.74 Million SEK | 145.428% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 316.163% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | -77.157% |
| Nanologica AB (publ) | -76 Thousand SEK | 26250.0% |
| SynAct Pharma AB | -778 Thousand SEK | 2654.499% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 10397.409% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 253.8% |
| Lipum AB (publ) | 53 Thousand SEK | -37398.113% |
| BioInvent International AB (publ) | 71.46 Million SEK | 72.189% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 45.249% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -1258.423% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 132593.333% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -1098.673% |
| Simris Alg AB (publ) | 2 Million SEK | -890.234% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 655.14% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 43.84% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 1994.566% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | -534.344% |